Cargando…

Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia

BACKGROUND: Histo-blood group antigens (HBGAs) which include the ABO and Lewis antigen systems have been known for determining predisposition to infections. For instance, blood group O individuals have a higher risk of severe illness due to V. cholerae compared to those with non-blood group O antige...

Descripción completa

Detalles Bibliográficos
Autores principales: Chisenga, Caroline C., Bosomprah, Samuel, Chilyabanyama, Obvious N., Alabi, Peter, Simuyandi, Michelo, Mwaba, John, Ng’ombe, Harriet, Laban, Natasha M., Luchen, Charlie C., Chilengi, Roma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869508/
https://www.ncbi.nlm.nih.gov/pubmed/36690955
http://dx.doi.org/10.1186/s12889-023-15051-w
_version_ 1784876782526136320
author Chisenga, Caroline C.
Bosomprah, Samuel
Chilyabanyama, Obvious N.
Alabi, Peter
Simuyandi, Michelo
Mwaba, John
Ng’ombe, Harriet
Laban, Natasha M.
Luchen, Charlie C.
Chilengi, Roma
author_facet Chisenga, Caroline C.
Bosomprah, Samuel
Chilyabanyama, Obvious N.
Alabi, Peter
Simuyandi, Michelo
Mwaba, John
Ng’ombe, Harriet
Laban, Natasha M.
Luchen, Charlie C.
Chilengi, Roma
author_sort Chisenga, Caroline C.
collection PubMed
description BACKGROUND: Histo-blood group antigens (HBGAs) which include the ABO and Lewis antigen systems have been known for determining predisposition to infections. For instance, blood group O individuals have a higher risk of severe illness due to V. cholerae compared to those with non-blood group O antigens. We set out to determine the influence that these HBGAs have on oral cholera vaccine immunogenicity and seroconversion in individuals residing within a cholera endemic area in Zambia. METHODOLOGY: We conducted a longitudinal study nested under a clinical trial in which samples from a cohort of 223 adults who were vaccinated with two doses of Shanchol™ and followed up over 4 years were used. We measured serum vibriocidal geometric mean titers (GMTs) at Baseline, Day 28, Months 6, 12, 24, 30, 36 and 48 in response to the vaccine. Saliva obtained at 1 year post vaccination was tested for HBGA phenotypes and secretor status using an enzyme-linked immunosorbent assay (ELISA). RESULTS: Of the 133/223 participants included in the final analysis, the majority were above 34 years old (58%) and of these, 90% were males. Seroconversion rates to V. cholerae O1 Inaba with non-O (23%) and O (30%) blood types were comparable. The same pattern was observed against O1 Ogawa serotype between non-O (25%) and O (35%). This trend continued over the four-year follow-up period. Similarly, no significant differences were observed in seroconversion rates between the non-secretors (26%) and secretors (36%) against V. cholerae O1 Inaba. The same was observed for O1 Ogawa in non-secretors (22%) and the secretors (36%). CONCLUSION: Our results do not support the idea that ABO blood grouping influence vaccine uptake and responses against cholera.
format Online
Article
Text
id pubmed-9869508
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98695082023-01-24 Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia Chisenga, Caroline C. Bosomprah, Samuel Chilyabanyama, Obvious N. Alabi, Peter Simuyandi, Michelo Mwaba, John Ng’ombe, Harriet Laban, Natasha M. Luchen, Charlie C. Chilengi, Roma BMC Public Health Research BACKGROUND: Histo-blood group antigens (HBGAs) which include the ABO and Lewis antigen systems have been known for determining predisposition to infections. For instance, blood group O individuals have a higher risk of severe illness due to V. cholerae compared to those with non-blood group O antigens. We set out to determine the influence that these HBGAs have on oral cholera vaccine immunogenicity and seroconversion in individuals residing within a cholera endemic area in Zambia. METHODOLOGY: We conducted a longitudinal study nested under a clinical trial in which samples from a cohort of 223 adults who were vaccinated with two doses of Shanchol™ and followed up over 4 years were used. We measured serum vibriocidal geometric mean titers (GMTs) at Baseline, Day 28, Months 6, 12, 24, 30, 36 and 48 in response to the vaccine. Saliva obtained at 1 year post vaccination was tested for HBGA phenotypes and secretor status using an enzyme-linked immunosorbent assay (ELISA). RESULTS: Of the 133/223 participants included in the final analysis, the majority were above 34 years old (58%) and of these, 90% were males. Seroconversion rates to V. cholerae O1 Inaba with non-O (23%) and O (30%) blood types were comparable. The same pattern was observed against O1 Ogawa serotype between non-O (25%) and O (35%). This trend continued over the four-year follow-up period. Similarly, no significant differences were observed in seroconversion rates between the non-secretors (26%) and secretors (36%) against V. cholerae O1 Inaba. The same was observed for O1 Ogawa in non-secretors (22%) and the secretors (36%). CONCLUSION: Our results do not support the idea that ABO blood grouping influence vaccine uptake and responses against cholera. BioMed Central 2023-01-23 /pmc/articles/PMC9869508/ /pubmed/36690955 http://dx.doi.org/10.1186/s12889-023-15051-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chisenga, Caroline C.
Bosomprah, Samuel
Chilyabanyama, Obvious N.
Alabi, Peter
Simuyandi, Michelo
Mwaba, John
Ng’ombe, Harriet
Laban, Natasha M.
Luchen, Charlie C.
Chilengi, Roma
Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia
title Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia
title_full Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia
title_fullStr Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia
title_full_unstemmed Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia
title_short Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia
title_sort assessment of the influence of abo blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in zambia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869508/
https://www.ncbi.nlm.nih.gov/pubmed/36690955
http://dx.doi.org/10.1186/s12889-023-15051-w
work_keys_str_mv AT chisengacarolinec assessmentoftheinfluenceofabobloodgroupsonoralcholeravaccineimmunogenicityinacholeraendemicareainzambia
AT bosomprahsamuel assessmentoftheinfluenceofabobloodgroupsonoralcholeravaccineimmunogenicityinacholeraendemicareainzambia
AT chilyabanyamaobviousn assessmentoftheinfluenceofabobloodgroupsonoralcholeravaccineimmunogenicityinacholeraendemicareainzambia
AT alabipeter assessmentoftheinfluenceofabobloodgroupsonoralcholeravaccineimmunogenicityinacholeraendemicareainzambia
AT simuyandimichelo assessmentoftheinfluenceofabobloodgroupsonoralcholeravaccineimmunogenicityinacholeraendemicareainzambia
AT mwabajohn assessmentoftheinfluenceofabobloodgroupsonoralcholeravaccineimmunogenicityinacholeraendemicareainzambia
AT ngombeharriet assessmentoftheinfluenceofabobloodgroupsonoralcholeravaccineimmunogenicityinacholeraendemicareainzambia
AT labannatasham assessmentoftheinfluenceofabobloodgroupsonoralcholeravaccineimmunogenicityinacholeraendemicareainzambia
AT luchencharliec assessmentoftheinfluenceofabobloodgroupsonoralcholeravaccineimmunogenicityinacholeraendemicareainzambia
AT chilengiroma assessmentoftheinfluenceofabobloodgroupsonoralcholeravaccineimmunogenicityinacholeraendemicareainzambia